Effect of statins in preventing contrast-induced nephropathy

Xie, Hongzhi; Ye, Yicong; Shan, Guangliang; Zhang, Shuyang; Fang, Quan; Yang, Deyan; Zeng, Yong

doi:10.1097/mca.0000000000000148

Cited by 9 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[11][12][13] This may also be true for simvastatin, although it is not yet reported. Additional evidence suggests simvastatin exerts neuroprotection via multiple mechanisms that include reduction of proinflammatory cytokines, 7,14 promotion of angiogenesis and neurogenesis, 1,15,16 and reduction of vasospasm. 17,18 Simvastatin has also been implicated in altering levels of specific genes associated with apoptosis (c-fos, c-myc, H1.2, and Bcl-2) and there is evidence suggesting that chronic administration may lead to statin accumulation in the brain.…”

Section: Introductionmentioning

confidence: 99%

Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy

Mountney

Bramlett

Dixon

et al. 2016

Journal of Neurotrauma

View full text Add to dashboard Cite

Simvastatin, the fourth drug selected for testing by Operation Brain Trauma Therapy (OBTT), is a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor used clinically to reduce serum cholesterol. In addition, simvastatin has demonstrated potent antineuroinflammatory and brain edema reducing effects and has shown promise in promoting functional recovery in pre-clinical models of traumatic brain injury (TBI). The purpose of this study was to assess the potential neuroprotective effects of oral administration of simvastatin on neurobehavioral, biomarker, and histopathological outcome measures compared across three pre-clinical TBI animal models. Adult male Sprague-Dawley rats were exposed to either moderate fluid percussion injury (FPI), controlled cortical impact injury (CCI), or penetrating ballistic-like brain injury (PBBI). Simvastatin (1 or 5 mg/kg) was delivered via oral gavage at 3 h post-injury and continued once daily out to 14 days post-injury. Results indicated an intermediate beneficial effect of simvastatin on motor performance on the gridwalk (FPI), balance beam (CCI), and rotarod tasks (PBBI). No significant therapeutic benefit was detected, however, on cognitive outcome across the OBTT TBI models. In fact, Morris water maze (MWM) performance was actually worsened by treatment in the FPI model and scored full negative points for low dose in the MWM latency and swim distance to locate the hidden platform. A detrimental effect on cortical tissue loss was also seen in the FPI model, and there were no benefits on histology across the other models. Simvastatin also produced negative effects on circulating glial fibrillary acidic protein biomarker outcomes that were evident in the FPI and PBBI models. Overall, the current findings do not support the beneficial effects of simvastatin administration over 2 weeks post-TBI using the oral route of administration and, as such, it will not be further pursued by OBTT.

show abstract

Section: Introductionmentioning

confidence: 99%

Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy

Mountney

Bramlett

Dixon

et al. 2016

Journal of Neurotrauma

View full text Add to dashboard Cite

show abstract

“…56,57 This statin-related effect seems to be dose dependent with different statins exerting similar protection as reported by recent meta-analyses. 57,58 These data support the initiation of statin therapy before CM exposure, even for a short-term period, to prevent incidence of CIN. 59 Of note, pentoxifylline, despite showing renoprotective effects in animal studies, 60 did not prevent CIN development in clinical trials.…”

mentioning

confidence: 58%

Contrast-Induced Nephropathy

et al. 2014

View full text Add to dashboard Cite

Contrast-induced nephropathy (CIN) represents an important adverse effect of contrast media (CM) administration. Contrast-induced nephropathy is associated with prolonged hospitalization as well as increased cardiovascular morbidity, renal morbidity, and all-cause mortality. Several risk factors may predict CIN incidence, and various scores and ratios have been proposed to identify high-risk patients. Novel biomarkers may provide an earlier diagnosis of CIN. A multifactorial approach is required for CIN prevention including hydration, administration of low- or iso-osmolar CM, minimizing CM volume, and statin administration. Renal function may deteriorate after CM administration, even in the absence of CIN. Therefore, this deterioration may not be an "all or none" phenomenon; it may well occur in many patients receiving CM, with/without CIN, and may prove to be an underestimated risk factor. Patients should be followed up for longer periods as outpatients after CM exposure to assess kidney function and predict subsequent increased morbidity and mortality.

show abstract

Prevention of Contrast-Induced Acute Kidney Injury: an Update

Chalikias

Drosos

Tziakas

2016

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

Contrast-induced acute kidney injury (CI-AKI) is a common complication of intravascular administration of contrast media used in coronary angiography, percutaneous coronary intervention and other diagnostic and interventional procedures. This review article aims at summarizing the published literature regarding the prevention of CI-AKI, by focusing on available high-quality meta-analyses addressing this matter. Apart from adequate hydration, a number of pharmacologic agents have been proposed as potential candidates to be included in the routine preparation, prior to the patient's arrival in the cardiac catheterization laboratory. Among them, statins and N-acetylcysteine appear to be the most extensively studied ones. Throughout this article we present the available data on CI-AKI prevention and provide a critical clinical appraisal, as well as a summary of currently available guidelines.

show abstract

Effect of statins in preventing contrast-induced nephropathy

Abstract: Pretreatment with statins before angiography is effective in preventing CIN and may reduce the risk of adverse clinical events. However, the optimal dose and duration for statin pretreatment are still unknown.

Cited by 9 publications

References 44 publications

Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy

Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy

Contrast-Induced Nephropathy

Prevention of Contrast-Induced Acute Kidney Injury: an Update

Contact Info

Product

Resources

About